Genetic: AAV5-hRKp.RPGR Intermediate Dose

Phase 3

Genetic: AAV5-hRKp.RPGR Intermediate Dose is one of 3 therapeutic programs targeting X-Linked Retinitis Pigmentosa. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

X-Linked Retinitis PigmentosaActive, not recruiting

X-Linked Retinitis PigmentosaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in X-Linked Retinitis Pigmentosa

#DrugCompanyPhaseTrials

Genetic: AAV5-Hrkp.rpgr

Johnson & Johnson

Phase 3

1 2

Genetic: AAV5-hRKp.RPGR Intermediate Dose

Johnson & Johnson

Phase 3

1 3

AAV5-Hrkp.rpgr

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Active, not recruiting

X-Linked Retinitis Pigmentosa

NCT04794101

Clinical

Trials by Indication[1]

X-Linked Retinitis Pigmentosa1 trial

Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04794101·97 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Genetic: AAV5-hRKp.RPGR Intermediate Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Genetic: AAV5-hRKp.RPGR Intermediate Dose. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Genetic: AAV5-hRKp.RPGR Intermediate Dose

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

X-Linked Retinitis Pigmentosa1 trial

References

Drug Info

Quick Facts

Related News